Arsanis closes Series A financing for $10 million Arsanis, Inc, a recently founded biotechnology company focused on the advancement of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A funding with a complete funding amount of $10 million. Proceeds from the initial financing will be used to advance several programs in the anti-microbial infectious disease area. The financing involved equivalent contributions from OrbiMed Advisors, Polaris Venture Companions and SV Existence Sciences tadalafil online here . Managing Companions, Carl Gordon, Terry McGuire and Mike Ross joined the founders on Arsanis’ Panel of Directors. Arsanis was founded in nov 2010 by Dr.